On the public citation graph

Advances in research on 3C-like protease (3CL pro ) inhibitors against SARS-CoV-2 since 2020

https://doi.org/10.1039/d2md00344a
0 signed · 116 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1007/s00281-017-0629-xopenalex-snapshot
Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology
inferredcites →https://doi.org/10.1007/s10930-020-09884-2openalex-snapshot
Covalent Versus Non-covalent Enzyme Inhibition: Which Route Should We Take? A Justification of the Good and Bad from Molecular Modelling Perspective
inferredcites →https://doi.org/10.1007/s40265-022-01692-5openalex-snapshot
Nirmatrelvir Plus Ritonavir: First Approval
inferredcites →https://doi.org/10.1016/j.bmc.2020.115860openalex-snapshot
Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors
inferredcites →https://doi.org/10.1016/j.bmcl.2006.11.044openalex-snapshot
A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds
inferredcites →https://doi.org/10.1016/j.bmcl.2012.11.026openalex-snapshot
Inhibition of norovirus 3CL protease by bisulfite adducts of transition state inhibitors
inferredcites →https://doi.org/10.1016/j.cell.2020.02.052openalex-snapshot
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
inferredcites →https://doi.org/10.1016/j.cell.2020.03.035openalex-snapshot
A Genomic Perspective on the Origin and Emergence of SARS-CoV-2
inferredcites →https://doi.org/10.1016/j.cmi.2020.04.040openalex-snapshot
Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19
inferredcites →https://doi.org/10.1016/j.ejmech.2020.112702openalex-snapshot
Potent inhibitors of SARS-CoV-2 3C-like protease derived from N-substituted isatin compounds
inferredcites →https://doi.org/10.1016/j.ejmech.2020.112711openalex-snapshot
The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020
inferredcites →https://doi.org/10.1016/j.ejmech.2021.113390openalex-snapshot
Structure-based drug design of an inhibitor of the SARS-CoV-2 (COVID-19) main protease using free software: A tutorial for students and scientists
inferredcites →https://doi.org/10.1016/j.ejmech.2021.113584openalex-snapshot
Improved SARS-CoV-2 Mpro inhibitors based on feline antiviral drug GC376: Structural enhancements, increased solubility, and micellar studies
inferredcites →https://doi.org/10.1016/j.ejmech.2021.113789openalex-snapshot
Discovery of juglone and its derivatives as potent SARS-CoV-2 main proteinase inhibitors
inferredcites →https://doi.org/10.1016/j.ijantimicag.2020.106055openalex-snapshot
Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors
inferredcites →https://doi.org/10.1016/j.jmb.2007.06.001openalex-snapshot
A Mechanistic View of Enzyme Inhibition and Peptide Hydrolysis in the Active Site of the SARS-CoV 3C-like Peptidase
inferredcites →https://doi.org/10.1016/j.jmb.2020.11.024openalex-snapshot
Structural insights into SARS-CoV-2 proteins
inferredcites →https://doi.org/10.1016/j.jpsychores.2021.110561openalex-snapshot
The impact of the coronavirus (COVID-19) pandemic on individuals with gastrointestinal disorders: A protocol of an international collaborative study
inferredcites →https://doi.org/10.1016/s0006-291x(67)80055-xopenalex-snapshot
On the size of the active site in proteases. I. Papain
inferredcites →https://doi.org/10.1021/acs.jcim.1c00851openalex-snapshot
High-Throughput Virtual Screening and Validation of a SARS-CoV-2 Main Protease Noncovalent Inhibitor
inferredcites →https://doi.org/10.1021/acs.jmedchem.0c01063openalex-snapshot
Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19
inferredcites →https://doi.org/10.1021/acs.jmedchem.0c02258openalex-snapshot
Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2
inferredcites →https://doi.org/10.1021/acs.jmedchem.1c00319openalex-snapshot
Structure-Guided Design of Conformationally Constrained Cyclohexane Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3CL Protease
inferredcites →https://doi.org/10.1021/acs.jmedchem.1c00509openalex-snapshot
Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors
inferredcites →https://doi.org/10.1021/acs.jmedchem.1c00598openalex-snapshot
Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CL pro )
inferredcites →https://doi.org/10.1021/acs.jmedchem.1c00616openalex-snapshot
Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and in Vitro Biological Stability
inferredcites →https://doi.org/10.1021/acs.jmedchem.1c00628openalex-snapshot
Self-Masked Aldehyde Inhibitors: A Novel Strategy for Inhibiting Cysteine Proteases
inferredcites →https://doi.org/10.1021/acs.jmedchem.1c00665openalex-snapshot
3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents
inferredcites →https://doi.org/10.1021/acs.jmedchem.1c01037openalex-snapshot
Structure-Guided Design of Potent Inhibitors of SARS-CoV-2 3CL Protease: Structural, Biochemical, and Cell-Based Studies
inferredcites →https://doi.org/10.1021/acs.jmedchem.1c01214openalex-snapshot
Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure–Activity Relationship, and X-ray Structural Studies
inferredcites →https://doi.org/10.1021/acs.jmedchem.1c01475openalex-snapshot
Structural, Electronic, and Electrostatic Determinants for Inhibitor Binding to Subsites S1 and S2 in SARS-CoV-2 Main Protease
inferredcites →https://doi.org/10.1021/acs.jmedchem.1c02214openalex-snapshot
Penicillin Derivatives Inhibit the SARS-CoV-2 Main Protease by Reaction with Its Nucleophilic Cysteine
inferredcites →https://doi.org/10.1021/acs.jmedchem.2c00117openalex-snapshot
Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19
inferredcites →https://doi.org/10.1021/acs.jmedchem.5b01461openalex-snapshot
An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy
inferredcites →https://doi.org/10.1021/acs.jmedchem.9b01828openalex-snapshot
α‑Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment
inferredcites →https://doi.org/10.1021/acscombsci.0c00058openalex-snapshot
Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy
inferredcites →https://doi.org/10.1021/bi400604topenalex-snapshot
Evidence for Substrate Binding-Induced Zwitterion Formation in the Catalytic Cys-His Dyad of the SARS-CoV Main Protease
inferredcites →https://doi.org/10.1021/jacs.1c08060openalex-snapshot
Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity
inferredcites →https://doi.org/10.1038/nrmicro.2016.81openalex-snapshot
SARS and MERS: recent insights into emerging coronaviruses
inferredcites →https://doi.org/10.1038/nrmicro775openalex-snapshot
SARS — beginning to understand a new virus
inferredcites →https://doi.org/10.1038/s41467-020-16954-7openalex-snapshot
Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography
inferredcites →https://doi.org/10.1038/s41467-020-18096-2openalex-snapshot
Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
inferredcites →https://doi.org/10.1038/s41467-020-19662-4openalex-snapshot
Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site
inferredcites →https://doi.org/10.1038/s41467-021-20900-6openalex-snapshot
A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication
inferredcites →https://doi.org/10.1038/s41467-021-21060-3openalex-snapshot
Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors
inferredcites →https://doi.org/10.1038/s41467-021-26239-2openalex-snapshot
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19
inferredcites →https://doi.org/10.1038/s41564-022-01119-7openalex-snapshot
An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron
inferredcites →https://doi.org/10.1038/s41579-018-0118-9openalex-snapshot
Origin and evolution of pathogenic coronaviruses
inferredcites →https://doi.org/10.1038/s41580-021-00418-xopenalex-snapshot
Mechanisms of SARS-CoV-2 entry into cells
inferredcites →https://doi.org/10.1038/s41586-020-2223-yopenalex-snapshot
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
inferredcites →https://doi.org/10.1038/s41586-020-2665-2openalex-snapshot
Structures and distributions of SARS-CoV-2 spike proteins on intact virions
inferredcites →https://doi.org/10.1038/s41591-021-01283-zopenalex-snapshot
Post-acute COVID-19 syndrome
inferredcites →https://doi.org/10.1038/s41598-020-79357-0openalex-snapshot
Biochemical and biophysical characterization of the main protease, 3-chymotrypsin-like protease (3CLpro) from the novel coronavirus SARS-CoV 2
inferredcites →https://doi.org/10.1038/s42003-020-01577-xopenalex-snapshot
Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents
inferredcites →https://doi.org/10.1080/22221751.2020.1719902openalex-snapshot
Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan
inferredcites →https://doi.org/10.1093/chemse/bjaa081openalex-snapshot
Recent Smell Loss Is the Best Predictor of COVID-19 Among Individuals With Recent Respiratory Symptoms
inferredcites →https://doi.org/10.1093/cid/ciaa330openalex-snapshot
Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study
inferredcites →https://doi.org/10.1101/2022.08.10.503531openalex-snapshot
Development of highly potent non-covalent inhibitors of SARS-CoV-2 3CLpro
inferredcites →https://doi.org/10.1126/sciadv.abd4596openalex-snapshot
Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti–COVID-19 drug design
inferredcites →https://doi.org/10.1126/science.1085658openalex-snapshot
Coronavirus Main Proteinase (3CL pro ) Structure: Basis for Design of Anti-SARS Drugs
inferredcites →https://doi.org/10.1126/science.1085952openalex-snapshot
Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
inferredcites →https://doi.org/10.1126/science.1085953openalex-snapshot
The Genome Sequence of the SARS-Associated Coronavirus
inferredcites →https://doi.org/10.1126/science.abb3405openalex-snapshot
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
inferredcites →https://doi.org/10.1126/science.abb4489openalex-snapshot
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
inferredcites →https://doi.org/10.1126/science.abf1611openalex-snapshot
SARS-CoV-2 M pro inhibitors with antiviral activity in a transgenic mouse model
inferredcites →https://doi.org/10.1126/science.abg5827openalex-snapshot
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
inferredcites →https://doi.org/10.1126/science.abl4784openalex-snapshot
An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
inferredcites →https://doi.org/10.1128/cmr.00102-14openalex-snapshot
Middle East Respiratory Syndrome Coronavirus: Another Zoonotic Betacoronavirus Causing SARS-Like Disease
inferredcites →https://doi.org/10.1186/s13578-021-00643-zopenalex-snapshot
SARS-CoV-2: from its discovery to genome structure, transcription, and replication
inferredcites →https://doi.org/10.1213/ane.0000000000004845openalex-snapshot
Coronaviruses and SARS-CoV-2: A Brief Overview
inferredcites →https://doi.org/10.3201/eid2602.190697openalex-snapshot
Middle East Respiratory Syndrome Coronavirus Transmission
inferredcites →https://doi.org/10.3389/fchem.2021.622898openalex-snapshot
Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease
inferredcites →https://doi.org/10.3390/molecules27082561openalex-snapshot
Covalent Reversible Inhibitors of Cysteine Proteases Containing the Nitrile Warhead: Recent Advancement in the Field of Viral and Parasitic Diseases
inferredcites →https://doi.org/10.4155/fmc-2020-0118openalex-snapshot
Covalent Inhibitors: Back on track?
inferredcites →https://doi.org/10.4161/hv.27464openalex-snapshot
Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate
inferredcites →https://doi.org/10.6023/cjoc1202132openalex-snapshot
Application of Nitrile in Drug Design

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.1002/9781394225156.ch1openalex-snapshot
Nirmatrelvir (Paxlovid with Ritonavir): A 3‐Chymotrypsin‐like Protease Inhibitor for Treating SARS‐CoV‐2 Infection
inferred← citeshttps://doi.org/10.1002/cmdc.70459openalex-snapshot
Design, Synthesis, and Structure–Activity Relationship Studies of Novel 3CL pro Inhibitors
inferred← citeshttps://doi.org/10.1007/s00044-023-03174-zopenalex-snapshot
Computer-aided design, synthesis and evaluation of new SARS-CoV-2 Mpro inhibitors based on 1,5,6,7-tetrahydro-4H-indazol-4-one scaffold
inferred← citeshttps://doi.org/10.1007/s00705-026-06667-5openalex-snapshot
SARS-CoV-2 3CL protease interaction with host factors – identifying novel drug targets
inferred← citeshttps://doi.org/10.1007/s11696-023-02804-5openalex-snapshot
Fluorine-a small magic bullet atom in the drug development: perspective to FDA approved and COVID-19 recommended drugs
inferred← citeshttps://doi.org/10.1016/b978-0-443-36518-8.00023-0openalex-snapshot
Targeting 3CLpro for broad-spectrum antiviral therapy: Structural insights, inhibitor development, and the future of PROTACs
inferred← citeshttps://doi.org/10.1016/j.arabjc.2024.105713openalex-snapshot
Synthesis, evaluation, and computational chemistry of novel selenenyl sulfides as 3C protease inhibitors with strong cell-based antiviral activity
inferred← citeshttps://doi.org/10.1016/j.bioorg.2023.106390openalex-snapshot
Green and efficient one-pot three-component synthesis of novel drug-like furo[2,3-d]pyrimidines as potential active site inhibitors and putative allosteric hotspots modulators of both SARS-CoV-2 MPro and PLPro
inferred← citeshttps://doi.org/10.1016/j.bioorg.2026.110402openalex-snapshot
Design, synthesis, and structural characterization of covalent tetrahydroquinoline-based inhibitors of coronavirus 3CLpro
inferred← citeshttps://doi.org/10.1016/j.bioorg.2026.110561openalex-snapshot
Indole-based peptidomimetic maleimides as SARS-CoV-2 Mpro inhibitor scaffolds compatible with reversible covalent inhibition: Warhead optimization and broad in vitro antiviral activity
inferred← citeshttps://doi.org/10.1016/j.bmcl.2024.129679openalex-snapshot
Synthesis, SARS-CoV-2 main protease inhibition, molecular docking and in silico ADME studies of furanochromene-quinoline hydrazone derivatives
inferred← citeshttps://doi.org/10.1016/j.ejmech.2023.115512openalex-snapshot
Design, synthesis and biological evaluation of peptidomimetic benzothiazolyl ketones as 3CLpro inhibitors against SARS-CoV-2
inferred← citeshttps://doi.org/10.1016/j.ejmech.2023.115979openalex-snapshot
Development of de-novo coronavirus 3-chymotrypsin-like protease (3CLpro) inhibitors since COVID-19 outbreak: A strategy to tackle challenges of persistent virus infection
inferred← citeshttps://doi.org/10.1016/j.ejmech.2024.116707openalex-snapshot
N-acylbenzimidazoles as selective Acylators of the catalytic cystein of the coronavirus 3CL protease
inferred← citeshttps://doi.org/10.1016/j.ejmech.2025.118277openalex-snapshot
A new chemotype that opens the S2∗ pocket of the 3CL protease exhibits antiviral activity against SARS-CoV-2
inferred← citeshttps://doi.org/10.1016/j.jep.2025.120249openalex-snapshot
Mechanistic insights into the dual anti-COVID-19 and anti-inflammatory actions of Zhengqi tablets
inferred← citeshttps://doi.org/10.1016/j.molstruc.2026.145714openalex-snapshot
N-(Benzofuran-3-ylmethyl)isatin derivatives as potential SARS-CoV-2 main protease inhibitors: Synthesis, biological evaluation, kinetic analysis, and molecular modeling insights
inferred← citeshttps://doi.org/10.1016/j.pep.2023.106414openalex-snapshot
Improved expression and purification of highly-active 3 chymotrypsin-like protease from SARS-CoV-2
inferred← citeshttps://doi.org/10.1021/acsinfecdis.5c00680openalex-snapshot
Broad-Spectrum Peptidomimetic Inhibitors of Norovirus and Coronavirus 3C-like Proteases
inferred← citeshttps://doi.org/10.1021/acsmedchemlett.4c00637openalex-snapshot
Design, Synthesis, and Biological Evaluation of Peptidomimetic Tetrahydropyrrole Spirodihydroindolones as SARS-CoV-2 3CL Protease Inhibitors
inferred← citeshttps://doi.org/10.1021/acsomega.3c06040openalex-snapshot
Antiviral Effects of Pyrroloquinoline Quinone through Redox Catalysis To Prevent Coronavirus Infection
inferred← citeshttps://doi.org/10.1021/acsomega.5c07593openalex-snapshot
Chromene-Thiazole Derivatives as Potential SARS-CoV-2 M pro Inhibitors: Synthesis and Computational Studies
inferred← citeshttps://doi.org/10.1038/s41598-024-71305-6openalex-snapshot
A Gaussia luciferase reporter assay for the evaluation of coronavirus Nsp5/3CLpro activity
inferred← citeshttps://doi.org/10.1039/d4md00289jopenalex-snapshot
Inhibition of SARS-CoV-2 3CLpro by chemically modified tyrosinase from Agaricus bisporus
inferred← citeshttps://doi.org/10.1039/d4md00414kopenalex-snapshot
Asymmetric imidazole-4,5-dicarboxamide derivatives as SARS-CoV-2 main protease inhibitors: design, synthesis and biological evaluation
inferred← citeshttps://doi.org/10.1042/bcj20230027openalex-snapshot
Key allosteric and active site residues of SARS-CoV-2 3CLpro are promising drug targets
inferred← citeshttps://doi.org/10.1042/bsr20231395openalex-snapshot
3-chymotrypsin-like protease in SARS-CoV-2
inferred← citeshttps://doi.org/10.1109/tcbb.2024.3378470openalex-snapshot
TDFFM: Transformer and Deep Forest Fusion Model for Predicting Coronavirus 3C-Like Protease Cleavage Sites
inferred← citeshttps://doi.org/10.1177/17475198231184799openalex-snapshot
M pro -targeted anti-SARS-CoV-2 inhibitor-based drugs
inferred← citeshttps://doi.org/10.1186/s13065-025-01636-6openalex-snapshot
Triazolo pyrimidine derivatives of coumarin and benzocoumarin: green synthesis, biological activity screening study with in silico evaluation
inferred← citeshttps://doi.org/10.26434/chemrxiv-2024-rw78sopenalex-snapshot
The Third CACHE Challenge – Finding Ligands Targeting the Macrodomain of SARS-CoV-2 NSP3 Using AI-inspired and Knowledge-Based Approaches.
inferred← citeshttps://doi.org/10.3389/fcell.2023.1238027openalex-snapshot
Current state-of-the-art and potential future therapeutic drugs against COVID-19
inferred← citeshttps://doi.org/10.3389/fmicb.2023.1232453openalex-snapshot
Novel receptor, mutation, vaccine, and establishment of coping mode for SARS-CoV-2: current status and future
inferred← citeshttps://doi.org/10.3390/app15126544openalex-snapshot
In Silico Development of SARS-CoV-2 Non-Covalent Mpro Inhibitors: A Review
inferred← citeshttps://doi.org/10.3390/ijms27094107openalex-snapshot
MERS-Mpro Predictor: A Machine Learning-Based Tool for Rapid Screening of Potential MERS-CoV Main Protease Inhibitors
inferred← citeshttps://doi.org/10.3390/molecules30234568openalex-snapshot
Lipophilic Substances of the Leaves and Inflorescences of Centaurea scabiosa L.: Their Composition and Activity Against the Main Protease of SARS-CoV-2
inferred← citeshttps://doi.org/10.3390/pharmaceutics17111477openalex-snapshot
Screening-Identified Oxazole-4-Carboxamide KB-2777 Exhibits In Vitro Anti-Coronavirus Activity
inferred← citeshttps://doi.org/10.37349/eds.2024.00071openalex-snapshot
Bicyclic peptide-enhanced covalent inhibitor of SARS-CoV-2 3CL protease
inferred← citeshttps://doi.org/10.48130/mpb-2023-0009openalex-snapshot
Discovery of anti-SARS-CoV-2 agents from 38 Chinese patent drugs toward respiratory diseases via docking screening
inferred← citeshttps://doi.org/10.48130/mpb-2023-0010openalex-snapshot
Discovery of anti-SARS-CoV-2 agents from commercially available flavor via docking screening
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.